{"id":14914,"date":"2024-11-25T20:45:15","date_gmt":"2024-11-25T12:45:15","guid":{"rendered":"https:\/\/flcube.com\/?p=14914"},"modified":"2024-11-25T20:45:20","modified_gmt":"2024-11-25T12:45:20","slug":"lundbeck-financial-results","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14914","title":{"rendered":"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results"},"content":{"rendered":"\n<p>Denmark-based pharmaceutical company H. Lundbeck A\/S (<a href=\"OTCMKTS: HLBBF\">OTCMKTS: HLBBF<\/a>) has revealed its financial results for the third quarter and the first three quarters of 2024. For the three-month period, revenues increased by 18% year-on-year (YOY) in constant currency terms to DKK 5.722 billion (USD 805 million). Over the nine-month period, sales rose by 13% YOY to DKK 16.463 billion (USD 2.315 billion).<\/p>\n\n\n\n<p><strong>Strategic Brands Drive Growth<\/strong><br>Lundbeck\u2019s strategic brands were instrumental in driving this growth, generating DKK 12.116 billion (USD 1.704 billion) in sales, marking a 21% YOY increase. Notable performances include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Rexulti\/Rxulti (brexpiprazole), a serotonin-dopamine activity modulator for major depressive disorder and schizophrenia, which expanded by 16% over the 9-month period to DKK 3.806 billion (USD 531.7 million).<\/li>\n\n\n\n<li>Brintellix\/Trintellix (vortioxetine), an anti-depressant, saw a 14% growth to DKK 3.576 billion (USD 499.6 million).<\/li>\n\n\n\n<li>Abilify Maintena\/Asimtufii (aripiprazole), an antipsychotic drug, grew by 10% to DKK 2.618 billion (USD 365.8 million).<\/li>\n\n\n\n<li>Vyepti (eptinezumab), a migraine medication, soared by 76% YOY to DKK 2.116 billion (USD 295.6 million).<\/li>\n<\/ul>\n\n\n\n<p><strong>Geographic Market Performance<\/strong><br>Geographically, the US and Europe were the primary sources of growth, with sales up 14% and 12% YOY, respectively, reaching DKK 8.342 billion (USD 1.17 billion) and DKK 3.815 billion (USD 533 million). International Markets rose by 9% YOY to DKK 4.062 billion (USD 567.5 million), with China and Canada contributing to 43% of this growth.<\/p>\n\n\n\n<p><strong>Generic Pressure on Certain Drugs<\/strong><br>However, Lundbeck noted that several drugs are under pressure due to generic competition, including Lexapro (escitalopram) in Japan and Deanxit (flupenthixol, melitracen) in China, which may impact future revenue growth.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Denmark-based pharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has revealed its financial results for the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":14915,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1581,1580],"class_list":["post-14914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-h-lundbeck","tag-otcmkts-hlbbf"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based pharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has revealed its financial results for the third quarter and the first three quarters of 2024. For the three-month period, revenues increased by 18% year-on-year (YOY) in constant currency terms to DKK 5.722 billion (USD 805 million). Over the nine-month period, sales rose by 13% YOY to DKK 16.463 billion (USD 2.315 billion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14914\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14914\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T12:45:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-25T12:45:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/lundbeck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Danish Pharma H. Lundbeck A\\\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results\",\"datePublished\":\"2024-11-25T12:45:15+00:00\",\"dateModified\":\"2024-11-25T12:45:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/lundbeck.png\",\"keywords\":[\"Finanical Reports\",\"H. Lundbeck\",\"OTCMKTS: HLBBF\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14914#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14914\",\"name\":\"Danish Pharma H. Lundbeck A\\\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/lundbeck.png\",\"datePublished\":\"2024-11-25T12:45:15+00:00\",\"dateModified\":\"2024-11-25T12:45:20+00:00\",\"description\":\"Denmark-based pharmaceutical company H. Lundbeck A\\\/S (OTCMKTS: HLBBF) has revealed its financial results for the third quarter and the first three quarters of 2024. For the three-month period, revenues increased by 18% year-on-year (YOY) in constant currency terms to DKK 5.722 billion (USD 805 million). Over the nine-month period, sales rose by 13% YOY to DKK 16.463 billion (USD 2.315 billion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14914\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/lundbeck.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/lundbeck.png\",\"width\":1080,\"height\":720,\"caption\":\"Danish Pharma H. Lundbeck A\\\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14914#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Danish Pharma H. Lundbeck A\\\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results - Insight, China&#039;s Pharmaceutical Industry","description":"Denmark-based pharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has revealed its financial results for the third quarter and the first three quarters of 2024. For the three-month period, revenues increased by 18% year-on-year (YOY) in constant currency terms to DKK 5.722 billion (USD 805 million). Over the nine-month period, sales rose by 13% YOY to DKK 16.463 billion (USD 2.315 billion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14914","og_locale":"en_US","og_type":"article","og_title":"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14914","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-25T12:45:15+00:00","article_modified_time":"2024-11-25T12:45:20+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/lundbeck.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14914#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14914"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results","datePublished":"2024-11-25T12:45:15+00:00","dateModified":"2024-11-25T12:45:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14914"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14914#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/lundbeck.png","keywords":["Finanical Reports","H. Lundbeck","OTCMKTS: HLBBF"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14914#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14914","url":"https:\/\/flcube.com\/?p=14914","name":"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14914#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14914#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/lundbeck.png","datePublished":"2024-11-25T12:45:15+00:00","dateModified":"2024-11-25T12:45:20+00:00","description":"Denmark-based pharmaceutical company H. Lundbeck A\/S (OTCMKTS: HLBBF) has revealed its financial results for the third quarter and the first three quarters of 2024. For the three-month period, revenues increased by 18% year-on-year (YOY) in constant currency terms to DKK 5.722 billion (USD 805 million). Over the nine-month period, sales rose by 13% YOY to DKK 16.463 billion (USD 2.315 billion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14914#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14914"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14914#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/lundbeck.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/lundbeck.png","width":1080,"height":720,"caption":"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14914#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Danish Pharma H. Lundbeck A\/S Sees Strong Q3 and Q1-Q3 2024 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/lundbeck.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14914"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14914\/revisions"}],"predecessor-version":[{"id":14916,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14914\/revisions\/14916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14915"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}